Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects

Trial Profile

A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LATTE 2
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 06 Nov 2019 Results of comparison between HIV treatment satisfaction questionnaire status version and HIV treatment satisfaction questionnaire change version presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 31 Oct 2018 Week 160 results assessing the safety, efficacy and durability of long-acting CAB and RPV as two-drug IM maintenance therapy for HIV-1 infection, presented at the 14th International Congress on Drug Therapy and HIV Infection
    • 31 Oct 2018 Results assessing the impact of a dual cabotegravir and rilpivirine LA treatment regimen on CSF and plasma HIV-1 RNA at steady state in a subset of HIV-1 infected patients (n=18), presented at the 14th International Congress on Drug Therapy and HIV Infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top